Drugs / BZE2203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06904131 | May 2025 → Dec 2027 expected | female reproductive system neoplasm | Obstetrics & Gynecology Hospital of Fudan University | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-05-15 | Shanghai Cell Therapy Group Co.,Ltd | Results 【AACR 2025】上细前沿突破二 | 实体瘤研究重大进展：自分泌PD-1纳米抗体装甲化双靶向闪CAR-T疗效显著 shcell.com ↗
两例患者回输后均获得部分缓解（PR），1例持续缓解至M3肿瘤靶病灶消失，达到完全缓解（CR），临床疗效显著。 |
| 2025-04-07 | Shanghai Cell Therapy Group Co.,Ltd | Results AACR 2025前瞻 | 上海细胞治疗集团5项创新研究成果入选 shcell.com ↗
JL-Lightning CAR-T，a Next Generation Non-viral CAR-T without In-Vitro Culturing Procedure, Shows High Clinical Efficacy, Good Safety with Low Dosage |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-15 | Shanghai Cell Therapy Group Co.,Ltd | 【AACR 2025】上细前沿突破二 | 实体瘤研究重大进展：自分泌PD-1纳米抗体装甲化双靶向闪CAR-T疗效显著 shcell.com ↗ |
| 2025-04-07 | Shanghai Cell Therapy Group Co.,Ltd | AACR 2025前瞻 | 上海细胞治疗集团5项创新研究成果入选 shcell.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BZE2203 | “on Day 0, the participant receives reinfusion of BZE2203 (dose determined according to the dose-escalation requirements)” NCT06904131 ↗ |
| Target | MSLN | “MUC1-targeted CAR-T Cells with PD1 Nanobody MSLN Dual-target” NCT06904131 ↗ |
| Target | MUC1 | “MUC1-targeted CAR-T Cells with PD1 Nanobody MSLN Dual-target” NCT06904131 ↗ |